Print this page
-
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Kidney -
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.
Protocol: 082203Principal Investigator:
- Ryan Stephenson (Rutgers University)
Applicable Disease Sites: Kidney -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Pancreas
Melanoma, Skin
Colon
Ovary
Soft Tissue
Prostate
Kidney
Breast